Publication details
Denní terapie erektilní dysfunkce – pro koho a s jakými riziky?
| Title in English | Daily therapy of erectile dysfunction – who is it for, what are the risks? |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Urologie pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Other specializations of internal medicine |
| Keywords | erectile dysfunction; PDE-5 inhibitors; tadalafil |
| Description | Erectile dysfunction (ED) is defined as an inability to achieve and maintain an erection sufficient for satisfactory sexual intercourse. Phosfodiesterase type 5 (PDE5) inhibitors are first line oral medication for erectile dysfunction (ED). Tadalafil 5 mg was well tolerated and effective in clinical studies, it was alternative to the current on-demand dosing of tadalafil for men with ED. Patients and their sexual partners preferred once daily administration, mainly because longer efficacy, safety allowing a more spontaneous sexual life. |